Evidence map›Paper›PMID 26438819›Full record

ArticleThe Journal of biological chemistry2015

p21-activated Kinases (PAKs) Mediate the Phosphorylation of PREX2 Protein to Initiate Feedback Inhibition of Rac1 GTPase.

Douglas Barrows, Sarah M Schoenfeld, Cindy Hodakoski, Antonina Silkov, Barry Honig, Anthony Couvillon, Aliaksei Shymanets, Bernd Nürnberg, John M Asara, Ramon Parsons

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Tumorigenesis driven by the BRAFbioRxiv : the preprint server for biology · 2024
    Article
  9. Patterning of the cell cortex by Rho GTPases.Nature reviews. Molecular cell biology · 2024
    Review
  10. Targeting Rac and Cdc42 GEFs in Metastatic Cancer.Frontiers in cell and developmental biology · 2020
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Douglas BarrowsFrom the Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, the Department of Pharmacology, Columbia University, New York, New York 10032.
Sarah M SchoenfeldFrom the Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029.
Cindy HodakoskiFrom the Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029.
Antonina Silkovthe Department of Biochemistry and Molecular Biophysics, Howard Hughes Medical Institute, Columbia University, New York, New York 10032.
Barry Honigthe Department of Biochemistry and Molecular Biophysics, Howard Hughes Medical Institute, Columbia University, New York, New York 10032.
Anthony CouvillonCell Signaling Technology, Danvers, Massachusetts 01923.
Aliaksei Shymanetsthe Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls University Hospitals and Clinics, and Interfaculty Center of Pharmacogenomics and Pharmaceutical Research, University of Tübingen, 72074 Tübingen, Germany.
Bernd Nürnbergthe Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls University Hospitals and Clinics, and Interfaculty Center of Pharmacogenomics and Pharmaceutical Research, University of Tübingen, 72074 Tübingen, Germany.
John M Asarathe Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, and the Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115.
Ramon ParsonsFrom the Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, ramon.parsons@mssm.edu.
Columbia University · USIcahn School of Medicine at Mount Sinai · USUniversity of Tübingen · DEBeth Israel Deaconess Medical Center · USCell Signaling Technology (United States) · US

Funding

Tuberous Sclerosis-Pathway and PathogenesisP01CA120964 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI David J. Kwiatkowski · 2007 to 2026
$35.9M
COMPUTER STUDIES OF PROTEIN STRUCTURE AND FUNCTIONR01GM030518 · NIGMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI HONIG, BARRY H · 1985 to 2020
$4.5M
Mutual Regulation of PTEN and P-REX2a in Normal and Cancer CellsR01CA155117 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PARSONS, RAMON E · 2011 to 2017
$2.5M
Mechanisms of PTEN-Long Function in CancerR01CA184016 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PARSONS, RAMON E · 2014 to 2017
$1.4M
High Resolution Mass Spectrometry SystemS10OD010612 · OD · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ASARA, JOHN M · 2012 to 2012
$600k
NCI NIH HHS 5P01CA120964NCI NIH HHS P01 CA120964NCI NIH HHS R01 CA155117NCI NIH HHS R01CA155117NCI NIH HHS R01 CA184016NCI NIH HHS R01CA184016NIGMS NIH HHS R01 GM030518NIGMS NIH HHS R01GM030518NIH HHS 1S10OD010612NIH HHS S10 OD010612
6 · The paper itself

Abstract

Phosphatidylinositol 3,4,5-trisphosphate (PIP3)-dependent Rac exchanger 2 (PREX2) is a guanine nucleotide exchange factor (GEF) for the Ras-related C3 botulinum toxin substrate 1 (Rac1) GTPase, facilitating the exchange of GDP for GTP on Rac1. GTP-bound Rac1 then activates its downstream effectors, including p21-activated kinases (PAKs). PREX2 and Rac1 are frequently mutated in cancer and have key roles within the insulin-signaling pathway. Rac1 can be inactivated by multiple mechanisms; however, negative regulation by insulin is not well understood. Here, we show that in response to being activated after insulin stimulation, Rac1 initiates its own inactivation by decreasing PREX2 GEF activity. Following PREX2-mediated activation of Rac1 by the second messengers PIP3 or Gβγ, we found that PREX2 was phosphorylated through a PAK-dependent mechanism. PAK-mediated phosphorylation of PREX2 reduced GEF activity toward Rac1 by inhibiting PREX2 binding to PIP3 and Gβγ. Cell fractionation experiments also revealed that phosphorylation prevented PREX2 from localizing to the cellular membrane. Furthermore, the onset of insulin-induced phosphorylation of PREX2 was delayed compared with AKT. Altogether, we propose that second messengers activate the Rac1 signal, which sets in motion a cascade whereby PAKs phosphorylate and negatively regulate PREX2 to decrease Rac1 activation. This type of regulation would allow for transient activation of the PREX2-Rac1 signal and may be relevant in multiple physiological processes, including diseases such as diabetes and cancer when insulin signaling is chronically activated.

Indexed as

Guanine Nucleotide Exchange FactorsHEK293 CellsHumansp21-Activated KinasesPhosphorylationrac1 GTP-Binding ProteinSecond Messenger SystemsGuanine Nucleotide Exchange Factorsp21-Activated KinasesPREX2 protein, humanrac1 GTP-Binding ProteinRAC1 protein, humanG-protein-coupled receptor (GPCR)guanine nucleotide exchange factor (GEF)insulinphosphatidylinositide 3-kinase (PI 3-kinase)Phosphatidylinositol-3,4,5-trisphosphate-dependent RAC exchanger 2 (PREX2)Rac (Rac GTPase)serine/threonine-protein kinase PAK 1 (PAK1)signal transduction

Identifiers

PMID26438819
PMCPMC4661405
OpenAlexW2278904651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.